Arcus Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Arcus Biosciences, Inc. (RCUS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $4.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-02-25
- Arcus Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $4.00M, a 300.00% increase from fiscal 2024.
- Arcus Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $1.00M, a 66.67% decline from fiscal 2023.
- Arcus Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $3.00M, a 88.46% decline from fiscal 2022.
- Arcus Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $26.00M, a 52.94% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month as first filed |
|---|---|---|
| 2025-12-31 | $4.00M 10-K · filed 2026-02-25 | |
| 2024-12-31 | $1.00M 10-K · filed 2026-02-25 | |
| 2023-12-31 | $3.00M 10-K · filed 2026-02-25 | |
| 2022-12-31 | $26.00M 10-K · filed 2025-02-25 | |
| 2021-12-31 | $17.00M 10-K · filed 2024-02-21 | $17.40M 10-K · filed 2022-02-23 |
| 2020-12-31 | $7.00M 10-K · filed 2023-02-28 | $6.80M 10-K · filed 2021-02-25 |
| 2019-12-31 | $200.00K 10-K · filed 2022-02-23 | |
| 2018-12-31 | $600.00K 10-K · filed 2021-02-25 | |
| 2017-12-31 | $2.50M 10-K · filed 2019-03-05 | |
| 2016-12-31 | $1.20M 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |